204 related articles for article (PubMed ID: 26812881)
1. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.
Leitch C; Osdal T; Andresen V; Molland M; Kristiansen S; Nguyen XN; Bruserud Ø; Gjertsen BT; McCormack E
Oncotarget; 2016 Feb; 7(7):8105-18. PubMed ID: 26812881
[TBL] [Abstract][Full Text] [Related]
2. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
McCormack E; Haaland I; Venås G; Forthun RB; Huseby S; Gausdal G; Knappskog S; Micklem DR; Lorens JB; Bruserud O; Gjertsen BT
Leukemia; 2012 May; 26(5):910-7. PubMed ID: 22064349
[TBL] [Abstract][Full Text] [Related]
3. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
Liu N; Wang C; Wang L; Gao L; Cheng H; Tang G; Hu X; Wang J
Int J Mol Med; 2016 Jun; 37(6):1686-96. PubMed ID: 27082972
[TBL] [Abstract][Full Text] [Related]
5. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway.
Yang Q; Chen K; Zhang L; Feng L; Fu G; Jiang S; Bi S; Lin C; Zhou Y; Zhao H; Chen XL; Fu G; Xu B
Cancer Lett; 2019 Oct; 461():31-43. PubMed ID: 31301319
[TBL] [Abstract][Full Text] [Related]
6. Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia.
Forthun RB; Hellesøy M; Sulen A; Kopperud RK; Sjøholt G; Bruserud Ø; McCormack E; Gjertsen BT
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1729-1749. PubMed ID: 31111215
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
[TBL] [Abstract][Full Text] [Related]
8. Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.
Rücker FG; Lang KM; Fütterer M; Komarica V; Schmid M; Döhner H; Schlenk RF; Döhner K; Knudsen S; Bullinger L
Epigenetics; 2016 Jul; 11(7):517-25. PubMed ID: 27309669
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia.
Davood ZA; Shamsi S; Ghaedi H; Sahand RI; Mojtaba G; Mahdi T; Reza M; Ebrahimi MJ; Miri-Moosavi RS; Boosaliki S; Davood OM
Tumour Biol; 2016 Aug; 37(8):11001-6. PubMed ID: 26894600
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity.
Heo SK; Noh EK; Yoon DJ; Jo JC; Park JH; Kim H
PLoS One; 2014; 9(2):e98859. PubMed ID: 24918603
[TBL] [Abstract][Full Text] [Related]
12. ZEB1 serves as an oncogene in acute myeloid leukaemia via regulating the PTEN/PI3K/AKT signalling pathway by combining with P53.
Li L; Feng Y; Hu S; Du Y; Xu X; Zhang M; Peng X; Chen F
J Cell Mol Med; 2021 Jun; 25(11):5295-5304. PubMed ID: 33960640
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis.
Lu X; Ohata K; Kondo Y; Espinoza JL; Qi Z; Nakao S
Cancer Sci; 2010 Mar; 101(3):609-15. PubMed ID: 20028385
[TBL] [Abstract][Full Text] [Related]
14. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
Eriksson A; Chantzi E; Fryknäs M; Gullbo J; Nygren P; Gustafsson M; Höglund M; Larsson R
Leuk Res; 2017 Dec; 63():41-46. PubMed ID: 29100024
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
Terranova-Barberio M; Roca MS; Zotti AI; Leone A; Bruzzese F; Vitagliano C; Scogliamiglio G; Russo D; D'Angelo G; Franco R; Budillon A; Di Gennaro E
Oncotarget; 2016 Feb; 7(7):7715-31. PubMed ID: 26735339
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
ten Cate B; Samplonius DF; Bijma T; de Leij LF; Helfrich W; Bremer E
Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
[TBL] [Abstract][Full Text] [Related]
18. p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy.
Haaland I; Hjelle SM; Reikvam H; Sulen A; Ryningen A; McCormack E; Bruserud Ø; Gjertsen BT
Cells; 2021 Apr; 10(4):. PubMed ID: 33917201
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
Trus MR; Yang L; Suarez Saiz F; Bordeleau L; Jurisica I; Minden MD
Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.
Xie C; Edwards H; Lograsso SB; Buck SA; Matherly LH; Taub JW; Ge Y
Pediatr Blood Cancer; 2012 Dec; 59(7):1245-51. PubMed ID: 22488775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]